首页> 外文期刊>Academic emergency medicine : >Major adverse cardiac event rates in moderate‐risk patients: Does prior coronary disease matter?
【24h】

Major adverse cardiac event rates in moderate‐risk patients: Does prior coronary disease matter?

机译:Major adverse cardiac event rates in moderate‐risk patients: Does prior coronary disease matter?

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Despite negative troponins and nonischemic electrocardiograms (ECGs), patients at moderate risk for acute coronary syndrome (ACS) are frequently admitted. The objective of this study was to describe the major adverse cardiac event (MACE) rate in moderate‐risk patients and how it differs based on history of coronary artery disease (CAD). Methods A secondary analysis of the HEART Pathway implementation study was conducted. This prospective interrupted time‐series study accrued adults with possible ACS from three sites (November 2013–January 2016). This analysis excluded low‐risk patients determined by emergency providers' HEART Pathway assessments. Non–low‐risk patients were further classified as high risk, based on elevated troponin measures or ischemic ECG findings or as moderate risk, based on HEAR score?≥?4, negative troponin measures, and a nonischemic ECG. Moderate‐risk patients were then stratified by the presence or absence of prior CAD (MI, revascularization, or ≥70% coronary stenosis). MACE (death, myocardial infarction, or revascularization) at 30?days was determined from health records, insurance claims, and death index data. MACE rates were compared among groups using a chi‐square test and likelihood ratios (LRs) were calculated. Results Among 4,550 patients with HEART Pathway assessments, 24.8% (1,130/4,550) were high risk and 37.7% (1715/4550) were moderate risk. MACE at 30?days occurred in 3.1% (53/1,715; 95% confidence interval [CI]?= 2.3% to 4.0%) of moderate‐risk patients. Among moderate‐risk patients, MACE occurred in 7.1% (36/508, 95% CI?= 5.1% to 9.8%) of patients with known CAD versus 1.4% (17/1,207, 95% CI?= 0.9% to 2.3%) in patients without known prior CAD (p?

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号